CGRP mAb use is significantly associated with current antidepressant use for migraine (odds ratio [OR]=2.25; 95% confidence interval [CI]: 1.94–2.62), having a contraindication to triptans (OR=2.12; 95% CI: 1.87-2.41), current use of cardiovascular medication for migraine (OR=2.00; 95% CI: 1.71-2.34), and current use of 2+ recommended non-CGRP mAb preventive medications (OR=1.31; 95% CI: 1.05-1.65)
The results are from the OVERCOME survey, carried out in the USA in 2019-2020, in nearly 40,000 respondents, a quarter of whom had ever used a preventive medication. Of these, 19% (1,952/10,011) had ever used a CGRP mAb. Of the total sample of 39,113, only 5% (1,952) had ever used a CGRP mAb.
Compared to CGRP mAb ever users, CGRP mAb never users were older [mean (standard deviation) 42.7 (13.6) vs. 37.5 (12.0) years], more likely to be female (76.6% vs. 57.5%), to be White (71.7% vs. 60.6%), to have joint pain (42.5% vs. 30.5%), and to have psychiatric comorbidities (66.4% vs. 58.2%).
Reasons for starting the first CGRP mAb were efficacy (61.0%), dosing or delivery (47.5%), recommendation or request (43.3%), tolerability (31.7%), novelty (22.2%), access or economic (17.2%), and other (1.9%).
Ashina S, KIm G, Muenzel J et al. Factors associated with calcitonin gene-related peptide (CGRP) monoclonal antibody (mAb) ever versus never use: Results of the OVERCOME (US) study. Headache 2023; 63(Suppl. 1): 55 (IO-11)